Protocolo terapéutico de las enfermedades pulmonares intersticiales difusas

American Thoracic Society, 2000, Idiopathic pulmonary fibrosis: Diagnosis and treatment; joint statement of the American Thoracic Society and the European Respiratory Society, Am J Respir Crit Care Med., 161, 646, 10.1164/ajrccm.161.2.ats3-00 Ley, 2011, Clinical course and prediction of survival in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med., 183, 431, 10.1164/rccm.201006-0894CI Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med., 183, 788, 10.1164/rccm.2009-040GL Cottin, 2016, Pharmacological management., 196 Costabel, 2014, Pirfenidone in diopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events, Adv Ther., 31, 375, 10.1007/s12325-014-0112-1 Raghu, 2015, Am J Respir Crit Care Med., 192, e3, 10.1164/rccm.201506-1063ST Richeldi, 2016, Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials, Respir Med., 10.1016/j.rmed.2016.02.001 Richeldi, 2011, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N Engl J Med, 365, 1079, 10.1056/NEJMoa1103690 León-Román, 2021, Acute exacerbation of idiopathic pulmonary fibrosis: an algorithmic approach to diagnosis and management, J Intern Med., 289, 930, 10.1111/joim.13225 Xaubet, 2017, Guidelines for the medical treatment of idiopathic pulmonary fibrosis, Arch Bronconeumol., 53, 263, 10.1016/j.arbres.2016.12.011 Vacchi, 2020, Therapeutic options for the treatment of Intertitial lung disease related to connective tissue disease. A narrative Review, J Clin Med., 9, 1